Swiss National Bank Has $208.54 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Swiss National Bank decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 5.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,279,932 shares of the company’s stock after selling 74,400 shares during the period. Swiss National Bank owned about 0.28% of Zoetis worth $208,539,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Mission Wealth Management LP increased its stake in Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after acquiring an additional 59 shares during the last quarter. Hancock Whitney Corp grew its holdings in shares of Zoetis by 0.3% during the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after purchasing an additional 61 shares in the last quarter. Strategy Asset Managers LLC grew its holdings in shares of Zoetis by 3.5% during the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after purchasing an additional 62 shares in the last quarter. VeraBank N.A. increased its position in shares of Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after purchasing an additional 62 shares during the last quarter. Finally, Procyon Advisors LLC raised its stake in Zoetis by 1.4% in the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after purchasing an additional 63 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock worth $312,254 in the last 90 days. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $160.03 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33. The company has a market capitalization of $71.66 billion, a P/E ratio of 29.26, a PEG ratio of 2.78 and a beta of 0.94. The stock has a 50 day moving average price of $166.86 and a two-hundred day moving average price of $176.33.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.25%. Zoetis’s payout ratio is presently 36.56%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Piper Sandler increased their target price on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group began coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Finally, Stifel Nicolaus decreased their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.